Warning: The NCBI web site requires JavaScript to function. more...
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.
Breast Cancer Res. 2008;10(5):R82. Epub 2008 Sep 30.
Related citations
Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.
Mol Cancer. 2008 Nov 6;7:83.
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.
Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E.
BMC Cancer. 2009 Jul 1;9:217.
Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knüchel R, Dahl E.
BMC Cancer. 2008 May 30;8:154.
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, Knüchel R, Klopocki E, Sauter G, Simon R, Wieland WF, Walter B, Denzinger S, Hartmann A, Hammerschmied CG.
Oncogene. 2007 Aug 16;26(38):5680-91. Epub 2007 Mar 12.
[Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer].
Dahl E, Veeck J, An H, Wiesmann F, Klopocki E, Sauter G, Kristiansen G, Hartmann A, Knüchel R.
Verh Dtsch Ges Pathol. 2005;89:169-77. German.
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y.
Oncogene. 2005 Nov 24;24(53):7946-52.
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.
Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knüchel R, Dahl E.
Breast Cancer Res. 2009;11(3):R34. Epub 2009 Jun 15.
Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y, Tong D, Lou G, Zhang Y, Geng J.
Pathobiology. 2008;75(4):244-51. Epub 2008 Jun 26.
Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, Shao ZM.
Breast Cancer Res Treat. 2010 Feb;119(3):601-12. Epub 2009 Mar 20.
Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, Gazdar AF.
Clin Cancer Res. 2003 Dec 15;9(17):6389-94.
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.
Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E.
Oncogene. 2006 Jun 8;25(24):3479-88. Epub 2006 Jan 30.
Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis.
Luo J, Feng J, Lu J, Wang Y, Tang X, Xie F, Li W.
Med Oncol. 2010 Sep;27(3):791-7. Epub 2009 Aug 14.
Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.
Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, Lung RW, Chan MW, Chan AW, Lo KW, To KF.
BMC Cancer. 2010 Jun 3;10:253.
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.
Oncogene. 2008 Jan 31;27(6):865-76. Epub 2007 Jul 23.
Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG.
Cancer Res. 2001 Sep 15;61(18):6688-92.
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
Chim CS, Pang R, Fung TK, Choi CL, Liang R.
Leukemia. 2007 Dec;21(12):2527-36. Epub 2007 Sep 20.
Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M, Calvano JE, Ho GH, Orlow I, Cordón-Cardó C, Borgen PI, Van Zee KJ.
Cancer Genet Cytogenet. 2001 Mar;125(2):131-8.
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y.
Cancer Res. 2003 Jul 15;63(14):4174-80.
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GS, Zhong S, Robertson KD, Rha SY, Chan AT, Tao Q.
Lab Invest. 2007 Jul;87(7):644-50. Epub 2007 Mar 26.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on